

SITE OECD Key Biotech Indicators
FIGURE 3
TITLE Total biotechnology R&D expenditures in the business sector, 2011 or latest available year
SUBTITLE Millions of USD PPP
SOURCE OECD, Biotechnology Statistics Database, December 2012; and OECD, Main Science and Tech

	Total biotechnology R&D expenditures, Milli ons USD PPP (left-hand scale)	Year	Type of firm	Biotech R&D as a percentage of BERD (right-hand scale)
United States	22.030,0	2009	Biotech R&D firms	7,8
France	2.777,4	2010	Biotech R&D firms	9,1
Japan	1.230,1	2010	Biotech firms	1,2
Germany	1.221,5	2011	Dedicated biotech firms	2,1
Korea	1.082,7	2010	Biotech R&D firms	2,7
Canada	944,5	2007	Biotech R&D firms	7,2
Switzerland	922,3	2008	Biotech R&D firms	12,6
Spain	794,1	2010	Biotech R&D firms	7,6
Belgium	574,0	2006	Biotech R&D firms	12,6
Sweden (*)	534,7	2011	Biotech R&D firms	6,2
Italy	468,1	2010	Biotech R&D firms	3,6
Denmark	463,7	2009	Biotech R&D firms	11,0
Israel	430,8	2010	Biotech R&D firms	5,6
Netherlands (*)	420,2	2010	Biotech R&D firms	6,9
Ireland	380,5	2011	Biotech R&D firms	17,9
Austria	203,4	2010	Dedicated biotech firms	3,2
Norway	158,6	2010	Biotech R&D firms	6,5
Russian Federation (*)	137,6	2011	Biotech R&D firms	0,7
Australia	122,1	2010	Biotech R&D firms	1,1
Finland	110,4	2011	Biotech R&D firms	2,1
Czech Republic	80,4	2011	Biotech R&D firms	3,1
Slovenia (*)	71,1	2011	Biotech R&D firms	9,0
Poland	40,8	2011	Biotech firms	2,7
Portugal	38,0	2010	Biotech R&D firms	1,9
Estonia	30,0	2011	Biotech R&D firms	13,4
South Africa	19,0	2006	Dedicated biotech firms	0,8
Slovak Republic	10,7	2011	Biotech R&D firms	3,2

Country notes

For Australia and Japan, 2009 Business Expenditures on R&D (BERD) was used to calculate the biotech R&D intensity, 2010 BERD was not available.

For the Czech Republic, Estonia, Finland, France, Germany, Ireland, Poland, the Russian Federation, the Slovak Republic, Slovenia and Sweden 2010 Business Expenditures on R&D (BERD) was used to calculate the biotech R&D intensity, 2011 BERD was not available.